$6.35
0.63% yesterday
NYSE, Aug 21, 10:00 pm CET
ISIN
US04635X1028
Symbol
ATXS

Astria Therapeutics Stock price

$6.35
+0.09 1.44% 1M
-0.46 6.75% 6M
-2.59 28.97% YTD
-5.58 46.77% 1Y
-2.20 25.73% 3Y
-38.95 85.98% 5Y
-669.25 99.06% 10Y
-773.65 99.19% 20Y
NYSE, Closing price Thu, Aug 21 2025
+0.04 0.63%
ISIN
US04635X1028
Symbol
ATXS
Industry

Key metrics

Basic
Market capitalization
$356.1m
Enterprise Value
$96.9m
Net debt
positive
Cash
$259.2m
Shares outstanding
56.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.4
Financial Health
Equity Ratio
93.3%
Return on Equity
-29.5%
ROCE
-49.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | $-162.3m
EBIT
$-131.4m | $-152.4m
Net Income
$-116.9m | $-127.2m
Free Cash Flow
$-116.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
-22.4% | -36.6%
Net Income
-25.4% | -34.9%
Free Cash Flow
-43.8%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.0
FCF per Share
$-2.1
Short interest
6.5%
Employees
78
Rev per Employee
$0.0
Show more

Is Astria Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,014 stocks worldwide.

Astria Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Astria Therapeutics forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a Astria Therapeutics forecast:

Buy
93%
Hold
7%

Financial data from Astria Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 37 37
20% 20%
-
- Research and Development Expense 94 94
23% 23%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -131 -131
22% 22%
-
Net Profit -117 -117
25% 25%
-

In millions USD.

Don't miss a Thing! We will send you all news about Astria Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Astria Therapeutics Stock News

Neutral
Business Wire
9 days ago
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update. “Delivering on navenibart's best-in-class potential is our top priority, and enrollment in the global Phase ...
Neutral
Business Wire
16 days ago
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it has exclusively licensed development and commercialization rights in Japan to Kaken Pharmaceutical, Co., Ltd., a Japanese specialty pharmaceutical company, for navenibart, a long-acting investig...
Neutral
Business Wire
17 days ago
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 180,000 shares of Astria's common stock on August 1, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the gran...
More Astria Therapeutics News

Company Profile

Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.

Head office United States
CEO Jill Milne
Employees 78
Founded 2008
Website astriatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today